RBBP9抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: A375 cells, Primary antibody: P08680(RBBP9 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08680(RBBP9 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The RBBP9 (Retinoblastoma-Binding Protein 9) antibody is a tool used to study the RBBP9 protein, a serine hydrolase implicated in cellular signaling and cancer biology. RBBP9. also known as BGRBP or Brain-derived retinoblastoma-binding protein, interacts with the retinoblastoma (Rb) protein, a key tumor suppressor regulating cell cycle progression. Structurally, it contains a conserved α/β-hydrolase domain, though its enzymatic activity remains partially characterized. Research suggests RBBP9 may act as a Ser/Thr phosphatase or participate in lipid metabolism, influencing pathways like TGF-β signaling and apoptosis.

Elevated RBBP9 expression is observed in certain cancers, including pancreatic, liver, and breast cancers, where it may promote tumor growth by enhancing proliferative signals or evading growth suppression. The RBBP9 antibody enables detection and quantification of this protein in techniques like Western blotting, immunohistochemistry, and immunofluorescence. It is critical for investigating RBBP9's role in oncogenesis, its interaction networks, and its potential as a therapeutic target. Commercial antibodies are typically validated for specificity using knockout controls or siRNA-based silencing. Ongoing studies aim to clarify its molecular mechanisms and clinical relevance in disease progression and treatment resistance.